A trial looking at calderasib and durvalumab for non small cell lung cancer (KANDLELIT-015)

This trial is looking at adding calderasib to durvalumab for non small cell lung cancer.

It is open to people who:

• have non small cell lung cancer that has grown or spread in the chest but has not spread to other parts of the body

• can’t or don’t want to have surgery to treat their cancer

• have a gene change (mutation) called KRAS G12C in their lung cancer cells

You pronounce calderasib as kal-dair-ah-sib.